We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

The Incidence of Occult Hepatitis C Virus Infection in Hemodialysed Patients With Liver Enzymes Disturbances

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01054664
Recruitment Status : Unknown
Verified January 2010 by Meir Medical Center.
Recruitment status was:  Not yet recruiting
First Posted : January 22, 2010
Last Update Posted : January 22, 2010
Information provided by:
Meir Medical Center

Brief Summary:
To assess the incidence of occult hepatitis C virus in hemodialysed patients with mild impairment of liver enzymes

Condition or disease
Hemodialysed Patients With Impaired Liver Enzymes

Detailed Description:
occult hepatitis C virus will be checked in monocytes of hemodialyzed patients with permanent mild impairment of liver enzymes This population has no evidence of hepatitis B or C according to standard laboratory tests (HVC antibodies,HCV PCR, hepatitis B antibodies) Hepatitis C virus RNA will be performed in peripheral blood mononuclear cells of hemodialysed patients

Study Type : Observational
Estimated Enrollment : 30 participants
Observational Model: Cohort
Time Perspective: Prospective
Study Start Date : February 2010

Resource links provided by the National Library of Medicine

U.S. FDA Resources

impaired liver enzymes
normal liver enzymes
hepatitis C antibodies positive

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
hemodialysis patients with impaired liver enzymes

Inclusion Criteria:

  • Hemodialysed patients with impaired liver enzymes

Exclusion Criteria:

  • hepatitis B and C positive

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01054664

Contact: Eleonora Plotkin, MD 972 9 7472517 nora.plotkin@clalit.org.il

Plotkin Eleonora Not yet recruiting
Kfar Saba, Israel
Contact: Osnat Klein, MD    972 9 7472517    Klein.Osnat@clalit.org.il   
Sponsors and Collaborators
Meir Medical Center

Responsible Party: Plotkin Eleonora, Clalit Health services
ClinicalTrials.gov Identifier: NCT01054664     History of Changes
Other Study ID Numbers: nephrop003
First Posted: January 22, 2010    Key Record Dates
Last Update Posted: January 22, 2010
Last Verified: January 2010

Keywords provided by Meir Medical Center:
liver enzymes
peripheral mononuclear blood cells
hepatitis C